BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35361141)

  • 1. Molecular characterization of hepatitis B virus (HBV) isolated from a pediatric case of acute lymphoid leukemia, with a delayed response to antiviral treatment: a case report.
    Chen CY; Hajinicolaou C; Walabh P; Ingasia LAO; Song E; Kramvis A
    BMC Pediatr; 2022 Mar; 22(1):168. PubMed ID: 35361141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
    Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
    Jeon HJ; Jung SW; Park NH; Yang Y; Noh JH; Ahn JS; Kim HR; Lee JH; Shin JW
    Clin Mol Hepatol; 2017 Sep; 23(3):230-238. PubMed ID: 28669175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
    Lim L; Thompson A; Patterson S; George J; Strasser S; Lee A; Sievert W; Nicoll A; Desmond P; Roberts S; Marion K; Bowden S; Locarnini S; Angus P
    Liver Int; 2017 Jun; 37(6):827-835. PubMed ID: 27896895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection.
    Lee HW; Park JY; Lee JW; Yoon KT; Kim CW; Park H; Kim YS; Paik SK; Lee JI; Kim BK; Han KH; Ahn SH
    Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1348-1355.e2. PubMed ID: 30613003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
    Lee SH; Cheon GJ; Kim HS; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS; Jun BG; Don Kim Y; Jun DW; Sohn JH; Kim TY; Lee BS
    Antivir Ther; 2018; 23(3):219-227. PubMed ID: 28436380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
    Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice.
    Song JE; Lee CH; Kim BS
    Korean J Intern Med; 2019 Jul; 34(4):802-810. PubMed ID: 30959583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
    Lim YS; Lee YS; Gwak GY; Byun KS; Kim YJ; Choi J; An J; Lee HC; Yoo BC; Kwon SY
    Hepatology; 2017 Sep; 66(3):772-783. PubMed ID: 28370419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
    Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
    Lee YB; Jung EU; Kim BH; Lee JH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Cho EJ; Yu SJ; Park SJ; Kim YJ; Park JW; Lee YJ; Kim CM; Yoon JH; Kim CY; Lee HS
    Antimicrob Agents Chemother; 2015 Feb; 59(2):972-8. PubMed ID: 25421484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
    Kitrinos KM; Corsa A; Liu Y; Flaherty J; Snow-Lampart A; Marcellin P; Borroto-Esoda K; Miller MD
    Hepatology; 2014 Feb; 59(2):434-42. PubMed ID: 23939953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B].
    Choi K; Lee HM; Jun BG; Lee SH; Kim HS; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Kim YD; Cheon GJ
    Korean J Gastroenterol; 2015 Jan; 65(1):35-42. PubMed ID: 25603852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
    J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.
    Kozielewicz D; Halota W; Wietlicka-Piszcz M
    Hepatol Int; 2016 Mar; 10(2):302-9. PubMed ID: 26612013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.